AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04394000 — intervention group
Intervention type: OTHER
Intervention: thromboprofylaxis protocol
Description: This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
Study NCT04394000 — intervention group
Intervention type: OTHER
Intervention: standard protocol
Description: This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
Study NCT02944461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone 7.5 % gel
Description: Dapsone gel 7.5% applied once daily to truncal acne
Study NCT02417480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
Study NCT02417480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow habitual, usual diet
Description: Participants will be asked to consume their habitual, usual diet.
Study NCT02417480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow habitual, usual diet
Description: Participants will be asked to consume their habitual, usual diet.
Study NCT02872142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albutein 5%
Description: Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
Study NCT02872142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma Exchange will be performed using albutein 5% as the replacement solution.
Study NCT03156621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab SC Q2W
Study NCT03156621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo SC Q2W
Study NCT01266057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Starting dose of 200 mg by mouth every day for a 21 day cycle.
Study NCT01266057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Starting dose of 2 mg by mouth every day for a 21 day cycle.
Study NCT01266057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting dose of 200 mg by mouth per day for a 21 day cycle.
Study NCT01694186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAI insert
Study NCT01694186 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Study NCT00501943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avonex (Interferon beta 1a)
Study NCT00501943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex (Interferon beta 1a)
Study NCT00501943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Study NCT00501943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03016403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care Intervention
Description: The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
Study NCT03016403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
Study NCT05571163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Tablets
Study NCT01008046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined N-acetyl cysteine -CC
Description: N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
Study NCT01008046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined metformin-CC
Description: Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
Study NCT00930332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone hydrochloride
Description: Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)
Study NCT00930332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: within 48 hours of registration
Study NCT00930332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: if required
Study NCT00576407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue for Implantation (CTTI)
Description: Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
Study NCT01431573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake Therapy
Description: Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
Study NCT01431573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light box
Description: use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
Study NCT01431573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
Study NCT00638079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate oral suspension 625 mg/5 mL
Description: Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
Study NCT00638079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate oral suspension 625 mg/5 mL
Description: Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
Study NCT03952520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Approach (SA)
Description: The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
Study NCT03952520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Approach (TA)
Description: The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
Study NCT03779854 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT03779854 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Bone Marrow Transplantation
Description: Receive unmanipulated T cell replete BM
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Receive naive T-cell depleted PBSCs
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo CSF and blood sample collection
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03779854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAS-20
Description: See Detailed Study Description.
Study NCT02370290 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Clinical and imaging information collected
Study NCT02370290 — intervention group
Intervention type: OTHER
Intervention: Informational Intervention
Description: Clinical and imaging data collected
Study NCT02631603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administer Placebo as anti-inflammatory
Study NCT02631603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Administer Prednisolone as anti-inflammatory
Study NCT03122886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat Emulsion
Description: Given IV
Study NCT03122886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT01677338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc sulfur colloid
Description: PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
Study NCT02965209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motorized spiral enteroscopy
Description: Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
Study NCT01167179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led consultation
Description: Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
Study NCT00414869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX-1000
Description: 500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
Study NCT00414869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive powder matching NCX-1000
Study NCT03447379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 antagonist monotherapy
Description: P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
Study NCT03447379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin plus P2Y12 antagonist
Description: DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
Study NCT03488108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
Study NCT03488108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Foam
Description: Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
Study NCT02781506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
Study NCT02781506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SAbR
Description: SAbR (1-3 lesions)
Study NCT00608361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00608361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00311155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Description: Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
Study NCT05683236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
Study NCT05683236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort care
Description: Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
Study NCT05683236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain care
Description: Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
Study NCT05683236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary care
Description: The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
Study NCT03834662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID200
Description: A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
Study NCT01326637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Overview Document
Description: The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD.
Study NCT02725580 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AT-GTX-501
Description: CLN6 Gene delivered by Self-Complementary AAV9
Study NCT01025141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skeletal anchorage (MINISCREW)
Description: Skeletal anchorage
Study NCT01025141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental anchorage
Description: dental anchorage (reference)
Study NCT02252016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study NCT03328273 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceralasertib
Description: An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).